GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward…
Radware Schedules Conference Call for Its Second Quarter 2025 Earnings
TEL AVIV, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR),…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
Kia Announces June 2025 Global Sales Results
June 2025 global sales of 269,652 units, up 0.2% Y/yOutside of Korea,…
Rockefeller Foundation Supports BRAC to Empower Smallholder Farmers Across Asia and Africa
Through the 300,000 USD grant, BRAC will develop a program that aims…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss…
MSCI Announces the Results of the MSCI 2025 Global Market Accessibility Review
NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI), a leading provider of critical decision…
New Global Aesthetics Report: A Shift Towards Facial Surgery Globally as Eyelid Ranks Top Procedure
Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20,…